Singapore markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
79.53-0.54 (-0.67%)
At close: 04:00PM EDT
79.31 -0.22 (-0.28%)
Pre-market: 08:28AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close80.07
Bid79.48 x 600
Ask79.54 x 600
Day's range78.92 - 79.62
52-week range60.47 - 80.86
Avg. volume5,088,068
Market cap246.584B
Beta (5Y monthly)0.17
PE ratio (TTM)39.18
EPS (TTM)2.03
Earnings date25 Jul 2024
Forward dividend & yield1.45 (1.82%)
Ex-dividend date22 Feb 2024
1y target est86.17
  • Yahoo Finance

    AstraZeneca CFO: 'We've come a long way in our oncology portfolio'

    AstraZeneca is beginning to see momentum behind its oncology portfolio. CFO Aradhana Sarin says the work is only just beginning.

  • Zacks

    FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

    Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.

  • Business Wire

    FARXIGA approved in the US for the treatment of pediatric type-2 diabetes

    WILMINGTON, Del., June 12, 2024--AstraZeneca’s FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.1 The FDA approval was based on positive results from the pediatric T2NOW Phase III trial.2 FARXIGA was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycemic control.1